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Background: A major challenge in the development of cell based therapies for glioma is to deliver optimal
number of cells (therapeutic dose) to the tumor. Imaging tools such as magnetic resonance imaging (MRI), optical
imaging, positron emission tomography (PET) and single-photon emission computed tomography (SPECT) has
been used in cell tracking and/or biodistribution studies. In this study, we evaluate the dynamic biodistribution of
systemic injected labeled cells [human cord blood derived endothelial progenitor cells (EPCs) and cytotoxic T-cells
(CTLs)] in rat glioma model with in vivo SPECT imaging.
Methods: Human cord blood EPCs, T-cells and CD14+ cells (monocytes/dendritic cells) were isolated using the
MidiMACS system. CD14+ cells were converted to dendritic cells (DC) and also primed with U251 tumor cell line
lysate. T-cells were co-cultured with irradiated primed DCs at 10:1 ratio to make CTLs. Both EPCs and CTLs were
labeled with In-111-oxine at 37°C in serum free DMEM media. Glioma bearing animals were randomly assigned
into three groups. In-111 labeled cells or In-111 oxine alone were injected through tail vein and SPECT imaging
was performed on day 0, 1, and 3. In-111 oxine activity in various organs and tumor area was determined.
Histochemical analysis was performed to further confirm the migration and homing of injected cells at the
tumor site.
Results: EPCs and CTLs showed an In-111 labeling efficiency of 87.06 ± 7.75% and 70.8 ± 12.9% respectively.
Initially cell migration was observed in lung following inravenous administration of In-111 labeled cells and
decreased on day 1 and 3, which indicate re-distribution of labeled cells from lung to other organs. Relatively
higher In-111 oxine activity was observed in tumor areas at 24 hours in animals received In-111 labeled cells
(EPCs or CTLs). Histiological analysis revealed iron positive cells in and around the tumor area in animals that
received labeled cells (CTLs and EPCs).
Conclusion: We observed differential biodistribution of In-111-oxine labeled EPCs and CTLs in different organs
and intracranial glioma. This study indicates In-111 oxine based SPECT imaging is an effective tool to study the
biodistribution of therapeutically important cells.
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Human glioma is an aggressive, malignant brain tumor
and cure rate of presently available therapies (surgical re-
section, radiotherapy, and chemotherapy) are too poor
[1,2]. Cell based gene therapies are growing fast as a po-
tential alternative therapies for the glioma [3-5]. Cell based
delivery of therapeutic agents offers advantages over regu-
lar vector or viral based delivery due to the ability of cells
(such as stem cells) to cross tumor blood brain barrier
(TBBB) and for extended homing at the tumor site [6-8]
following systemic administration. Development and con-
tinual improvement of in vivo cell tracking methods are
important for ongoing efforts to improve the effectiveness
of cell-based therapies for glioma treatment [9]. In cell
based therapies, it is important to determine optimal
effective dose, monitor cell delivery, number of viable cells
and homing to improve the therapeutic effect at the tumor
site.
Imaging techniques are necessary to monitor the effi-
ciency of cell retention and dose determination in in
vivo preclinical models. Magnetic resonance imaging
(MRI) has been used in animal models for cell tracking
with the help of iron-oxide nanoparticles as probes
[10,11]. Studies have shown the capability of iron-oxide
nanoparticles for non-invasive MRI tracking of cell mi-
gration and engraftment [9,10]. Recently dual-modality
probes such as radiolabeled iron oxide nanoparticles
have been developed and shown the promising results
for biodistribution and diagnostic applications. These
probes can be detected by two different imaging modal-
ities (SPECT/PET or MRI) at the same time [12]. In
addition, these nanoparticles help in generating high sensi-
tivity (SPECT/PET) and high resolution (MRI) images
[12]. The main drawback of iron based nanoparticles is
their inability to distinguish live from dead cells. In
addition, iron-oxide nanoparticles induce hypointensities
on T2 or T2*-weighted images, which further hamper to
distinguish from hemorrhage. Recently manganese
oxide (MnO) based nanoparticles were developed to
overcome these limitations, which show high signal in-
tensity on T1-weighted images [13,14]. MnO based
nanoparticles have been used to label stem cells and
used in vivo MRI to track stem cell migration and en-
graftment [13,14]. However, MRI does not provide the
data on whole body biodistribution of labeled cells as
well as number of cell accumulation at the target site.
Positron emission tomography (PET) has been used in
combination with 18 F-fluorodeoxyglucose (18 F-FDG)
for cell tracking. However, long term tracking of cells
with PET imaging was difficult due to short half-life of
the probes [15,16]. SPECT is advantageous to monitor
administered cells for relatively longer time and to ob-
serve clearance of cells from different organs and hom-
ing at the tumor site [10,17]. For SPECT imaging, eitherIndium-111 (In-111)-oxine or Technetium-99m (Tc-
99m) based radiopharmaceuticals (such as Tc-99 m-
HMPAO), can be used to label cells. However, In-111-
oxine is better suited due to its longer half-life (2.8 days)
to monitor migration and homing of intravenously (IV)
administered cells to the site of tumor.
In the present study, we described the method of label-
ing of EPCs and CTLs with In-111-oxine and investigated
differential biodistribution of In-111-oxine labeled cells
using SPECT imaging in rat glioma models. SPECT scan-
ning helps to study the whole body and organ specific
biodistribution of the cells (EPCs and CTLs). Such infor-
mation would help determining the percent of adminis-
tered cells reaching target site (tumor area) and further




Human cord blood was collected under Henry Ford Health
System institutional review board (IRB) approved protocol
(3287) [9,17]. AC133+ EPCs were isolated using our previ-
ously published method [9,17]. Brief, AC133+ cells were
separated from human cord blood using ficoll gradient cen-
trifugation and further selected using the MidiMACS sys-
tem (Miltenyi, Auburn, CA) [9,17]. Collected EPCs were
maintained in hematopoietic stem cell media at 1 × 106
cells per ml in 5% CO2/95% air at 37°C [9,17]. To confirm
the purity of the isolated cells, flow-cytometry was done
using different AC133+ markers [9,17].
Preparation of Sensitized T-Cells (CTLs)
T-cells and CD14+ cells were isolated from human cord
blood as described in our previous published method [10].
CD14+ cells were converted to immature dendritic cells
(DC) [10]. Immature DCs were subjected maturation
process and primed with U251 cell lysate according our
published method [10]. Matured DCs were tested for
markers specific for DCs (CD14, CD86, CD83 and HLA-
DR) by flow-cytometry [10]. Sensitization of T-cells was
carried out according to our previous works [10]. Brief,
cryopreserved T-cells thawed and cultured overnight and
then co-cultured with irradiated primed DCs at 10:1 ratio
[10]. T-cell proliferation was determined by MTT assay
(ATCC) according to manufacturer instructions. After 6
days of co-culture the T-cells were collected by centrifuga-
tion and re-suspended in normal saline for further labeling
[10].
In111 oxine labeling of EPCs, and CTLs
Both EPCs and CTLs were labeled with In-111-oxine
(Anazao Health Corp, Tampa FL) at 37°C in normal sa-
line. Twenty million either EPCs or CTLs were incu-
bated with 37 MBq of In-111-oxine in 2 ml of serum
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for 20–25 minutes, the cells were centrifuged (1200 rpm
for 10 min) and washed twice with PBS. Cell viability
and percentage of labeling efficiency was calculated. Rats
were administered with 20 × 106 CTLs or 10 × 106 EPCs
or In-111 oxine alone for each respective animal and
iron-oxide labeling was also used to label small portion
of cells (CTLs or EPCs) to detect cell migration to the
tumor area using histochemistry [17].
Animal model
Athymic nude rats (6–8 weeks of age) (Charles River La-
boratory, Inc.) were anesthetized using ketamin/xylazine
mixture and were placed on a stereotactic head holder
[10,17]. The tumor was implanted according to our pub-
lished method [10,17]. Brief, a hole was drilled after expos-
ing the skull and U251 glioma tumor cells (4 × 105) were
injected stepwise followed by withdrawal of syringe
[10,17]. After syringe withdrawal, bone wax was used to
close the surgical hole and skin was sutured [10,17].
SPECT imaging and analysis
Glioma bearing nude rats were randomly assigned into
three groups; 1) animals receiving an tail vein administra-
tion of In-111-labeled EPCs (10 × 106 cells) (n = 6), 2) ani-
mal receiving tail vein injection of In-111 labeled CTLs
(20 × 106 cells) (n = 4), 3) animal receiving tail vein injec-
tion of equal amount of In-111 oxine (n = 6). After tail
vein injection of In-111-labeled cells or In-111-oxine
alone, SPECT scanning was performed on day 0 (1–3
hours post injection of labeled cells or In-111-oxine), day1
and 3. Once put on appropriate anesthesia using keta-
mine/xylazine (100/10 mg/kg), animals were scanned with
a SPECT imager (PRISM 3000 gamma camera, Picker,
USA) [17]. Whole body (neck to tail region) of the animal
was scanned followed by separate scan of the head region.
After imaging, rats were euthanized and perfused to col-
lect the organs for further analysis [17]. Acquired images
were processed using Bioscan software (HiSPECT, Wash-
ington DC) and Image J software (NIH, Bethesda MD).
The whole body radioactivity on day 0 upon administra-
tion of labeled cells or In-111-oxine was used as total ad-
ministered dose and activity in organs was calculated as
percentage of administered dose after decay correction.
Organ specific radioactivity and histochemistry
After day 3 SPECT imaging, animals were euthanized
using pentobarbital (150–200 mg/kg) and perfused with
3% paraformaldehyde. Tissue samples from heart, lung,
kidney, liver and spleen and brain were obtained. The
radioactivity was measured for all tissue samples using
gamma counter (Wizard 1420, PerkinElmer, USA).
Tissue sections from brain were prepared according to
our previous publications [10,17]. In brief, brain sampleswere made into 1-mm blocks and paraffin embedded. The
embedded blocks were cut into serial 10 μm sections and
prussian blue staining was used to visualize the iron within
FePro labeled cells. Brain tissue sections were stained with
prussian blue according to our published works to detect
the migration of administered labeled cells to the tumor
area [10,11,17]. Brief, fixed sections were de-paraffinized,
rehydrated, washed, and incubated for 30 min with 5% po-
tassium ferrocyanide in 5% hydrochloric acid, DAB en-
hanced, and counterstained with nuclear fast red. Prussian
blue stained sections were observed under light micro-
scope to determine the migration of labeled cells (EPCs or
CTLs) to tumor area [10,11,17].
Statistical analysis
The Student t test was used to evaluate differences between
rat groups, with P < 0.05 considered to be statistically sig-
nificant. All data was expressed as mean ± standard devi-
ation (± SD) unless stated otherwise.
Results
Labeling efficiency and cellular viability
EPCs and CTLs were labeled with In-111 oxine under sus-
pension conditions in normal saline. EPCs and CTLs
showed a labeling efficiency of 87.06 ± 7.75% and 70.8 ±
12.9% respectively. To test whether labeling with In-111-
oxine have any effect on viability of cells, we used trypan
blue dye exclusion test to measure the cell viability of la-
beled and unlabeled CTLs and EPCs. We tested the cell
viability immediately after cells labeled with In-111-oxine.
Both CTLs and EPCs showed similar viability (no signifi-
cant differences) following In-111-oxine labeling com-
pared to that of corresponding unlabeled CTLs or EPCs.
Biodistribution of In-111 labeled cells in different organs
In-111- CTLs, In-111-EPCs or In-111-oxine were injected
IV into glioma bearing nude rats. Biodistribution of radio-
activity in different organs and in tumors were determined
on days 0, 1 and 3 using SPECT imaging. In-111 oxine
injected animal showed identical activity from 3 to 72
hours in lung, heart, brain, and liver, while in spleen an in-
creased activity was observed at 72 hours (Figure 1). We
observed differences in biodistribution between CTLs and
EPCs, In-111 labeled CTLs showed higher activity in lung
at 3 hours scan compared to In-111 labeled EPCs
(Figure 1). However, 24 hours scanning showed clearance
of activity from the lung, which indicated redistribution of
In-111-CTLs to other organs. On the other hand, we
observed less activity of In-111-EPCs in the lung at all time
points compared to In-111-CTLs. Distribution of cell-
associated activities (both CTLs and EPCs) in different
organs was clearly different than that of activities seen in
animals which received In-111-oxine alone.
Figure 1 SPECT images showing biodistribution of IV administered In-111-oxine, In-111 labeled CTLs and EPCs: Biodistribution of
In-111-oxine alone did not showed any difference from 3 to 72 hours, but activity in spleen increased at 72 hours. Labeled CTLs showed
high activity in lung at 3 hours and redistribution at 24 and 72 hours. The activity of In-111-CTLs in liver increased from 3 hrs to 72 hours while activity
in spleen remained constant. Labeled EPCs showed activity in lung at 3 hours, which is much lower when compared to CTLs. The activity of
In-111-EPCs in liver and spleen did not change much with the time (3 to 72 hours).
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lung and spleen following IV administration of In-111-
oxine. We observed 23.05 ± 3.22%ID in the lung at 1
hour, which gradually increased to 25.16 ± 2.74%ID at 3
hours but the activity significantly decreased at 24 hours
(16.38 ± 3.43%ID) and 72 hours (13.28 ± 2.56%ID)
(Figure 2A). However, we did not observe similar shift of
radioactivity in the liver. The percentage of radioactivity
was not decreased over time and there was no signifi-
cant difference of In-111-oxine activity among different
time points (Figure 2A). Spleen showed significantly lessactivity of In-111-oxine compared to lung and liver and
similar to liver there was no change in activity over time.
We observed initial accumulation of In-111 labeled
CTLs in the lung (29.90 ± 4.90%ID at 1 hour to 30.18 ±
0.00%ID at 3 hours) but activity in lung was dramatically
decreased at later time point (4.07-2.34%ID at 24 hours),
which was further decreased at 72 hours (1.85 ± 1.31%
ID) (Figure 2B). However, In-111-CTLs activity in the
liver showed gradual increased at 24 hours and 72 hours,
which became significantly different compared to that of
2 hours (Figure 2B), while activity in spleen showed no
Figure 2 Graphical representation of percentage of activity in different organs with the time. Biodistribution study of IV injected In-111
oxine alone (A), In-111 labeled CTLs (B), In-111 labeled EPCs (C) and accumulation of In-111-CTLs and In-111-EPCs in glioma (D). In these graphs
we included 1 and 2 hours san data along with 3, 24 and 72 hours. (A) In-111-oxine alone did not show significant change in organ distribution
patterns from 1 to 72 hours. (B) Labeled CTLs showed 40% activity in lung at 2 hours, which dropped to 30% at 3 hours and further dropped
after 24 and 72 hours, which indicates redistribution for CTLs from lung. Liver and spleen did not showed difference from 1 to 72 hour scans.
(C) In-111 labeled EPCs showed lung associated activity at 1 hour scan but within 3 hours the activity was dropped by 68.4%, which indicates
rapid redistribution of EPCs from the lung. Liver and spleen did not showed significant difference in activity from 3 to 72 hours. (D) Percentage of
In-111 labeled CTLs and EPCs’ migration to tumor site and contralateral brain was determined in this graph at three time points (3, 24 and 72
hours). CTLs showed highest activity at 24 hours (0.8 ± 0.41%) compared to 3 and 72 hours. EPCs showed highest activity at 24 hours
(2.77 ± 2.3%) compared to 3 and 72 hours.
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(Figure 2B).
We observed different patterns of distribution for In-
111 labeled EPCs in lung compared to that of In-111-
CTLs or In-111-oxine. The accumulated In-111-EPCs in
the lung (38.02 ± 16.34%ID at 1 hour) started redistribu-
tion as early as 2 hours which became significantly lower
at 3 hours, which further reduced at 24 and 72 hours
(1.13 ± 0.49%ID at 72 hours) (Figure 2C). Early redistri-
bution from the lung was also supported by the in-
creased activity in the liver and spleen at 2 hours. Both
the activities in the liver and spleen remained stable
until 72 hours (55.55 ± 5.87%ID in liver and 7.5 ± 1.94%
ID in spleen) (Figure 2C).
We further analyzed migration of injected EPCs and
CTLs to the tumor area, where, we observed migration of
In-111-CTLs and EPCs to tumor site (Figures 2D and 3).
Both In-111-CTLs and In-111-EPCs showed migration to
tumors as early as 3 hours post injection. Comparatively
higher activity was observed in tumors at 24 hours of
post IV administration of In-111-CTLs or In-111-EPCs
(Figures 2D and 3). Semi-quantitative analysis showed
tumor specific accumulation of CTLs (0.8 ± 0.41%ID at
24 hours) and EPCs (2.7 ± 2.3%ID at 24 hours)(Figure 2D). There was almost negligible activity observed
on contra-lateral brain for both CTLs and EPCs.
To further confirm the SPECT image results, we iso-
lated organs (brain, liver, spleen, kidney, heart and lung)
after day 3 SPECT scanning and measured the radio-
activity in vitro using a gamma counter. We found out
that radioactivity in the isolated organs are consistent
with in vivo SPECT imaging data.
Histochemistry
Histochemistry based approach was used to further con-
firm the migration of CTLs and EPCs to the tumor area.
Brain sections were prepared and analyzed by staining to
determine EPCs and CTLs migration to tumors. We ob-
served iron positive cells in and around the tumor area
in animals that received iron oxides nanoparticles la-
beled CTLs and EPCs (Figure 4). Histochemistry results
further support the SPECT imaging findings of EPCs
and CTLs migration to the tumor area.
Discussion
Endothelial progenitor cells and CTLs have been shown
to migrate and home to implanted glioma [10,17]. In our
previous studies, we showed cord blood derived T-cells
Figure 3 SPECT images of biodistribution of labeled cells in brain region. In-111 oxine alone did not show any activity around the tumor
area. Accumulation of In-111 labeled CTLs in tumor area was seen within three hours and the activity further increased on 24 hour scans. In-111
labeled EPCs showed high activity around the tumor area in 3 hours scan, which was significantly higher compared to CTLs. 24 hours scan
showed further increase in the radioactivity. Note: The increased accumulation of cells after 24 hours of injection. Window levels of signals are
kept identical for all day for respective tumors.
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labeled with iron oxide to use as MRI probes to detect
glioma from radiation necrosis in rat glioma model [10].
Recently, we showed human cord blood derived EPCs
homing at glioma in rat models, where we used iron
oxide probes to label the EPCs and tracked them using
MRI [11,17]. MRI imaging has limitations to determine
the number of migrated labeled cells to the site of inter-
est and whole body biodistribution (different organs) in
animal using current set up of hardware and software.
To improve the applicability of cell based therapy in
cancers and to design effective therapeutic dose, it is im-
portant to determine their biodistribution and the rate
of migration to tumor site following systemic adminis-
tration. In this study, we used SPECT imaging in com-
bination with In-111-oxine labeling to determine
distribution of administered cells in whole body and in
rat model of glioma.
In-111-oxine is commercially available FDA approved
radioactive tracer, generally safe to use in humans
[18,19]. In-111-oxine widely used in cell labeling due to
its lipophilic nature, which passively diffuses into cells
and binds to intracytoplamic proteins [20,21]. Inaddition, half-life of In-111 is 2.8 days, which allows
monitoring of cell biodistribution for long period of time
(0 to 7 days) in animal models [22]. Before applying the
labeled cells in biodistribution study, it is important to
know the labeling efficiency and radio toxicity effects on
the viability of the cells. The labeling efficiency of In-
111-oxine was calculated for the CTLs and EPCs. EPCs
showed higher labeling efficiency than that of CTLs. It
was not unexpected that In-111-oxine cell labeling effi-
ciency varies with cell type [23]. Several studies showed
that In111-oxine labeling of human stem cells did not
affect the cell viability and stem cell characteristics
[24,25]. Our results with trypan blue dye exclusion assay
for cell viability also showed no differences in the viabil-
ity following In-111-oxine labeling when compared with
unlabeled cells. These results indicate that In-111 oxine
labeling of CTLs and EPCs did not affect cell viability
with the applied dose. These results are also in agree-
ment with previously published report [22].
In our previous studies, we have shown the migration
and accumulation of iron nanoparticles labeled CTLs
and EPCs to the sites of intracranial implanted glioma in
rat models by MRI [10,11]. However, MRI could not
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other organs. Although relative number of accumulated
cells in the tumor can be predicted by MRI, absolute
quantification of (%ID) the number of cell in the area of
interest is yet to be determined by MRI. We also used
SPECT analysis to determine the migration and accumu-
lation of genetically altered EPCs where cord blood de-
rived EPCs transduced to carry human sodium iodide
symporter (hNIS) gene and injected into glioma bearing
rats [17]. The accumulation of genetically altered EPCs
to the sites of glioma was detected by Tc-99 m-SPECT.
We could detect the accumulation EPCs at tumor site
but we were not able to determine the number of accu-
mulated EPCs. In this present study, whole body as well
as focal SPECT imaging revealed redistribution of
injected cells from the different organs (especially from
lung). In-111 labeling techniques allowed us to deter-
mine the number of accumulated cells (%ID) in different
organs as well as in the tumors. Based on the percent
ID, we determined the number of accumulated EPCs or
CTLs (around 200,000) at 24 hours. We observed an
early migration and homing of labeled CTLs and EPCs
at tumor site (within 3 hours of injection). This early mi-
gration of cells indicates that both CTLs and EPCs have
high affinity and early homing properties to the glioma
site. The migration of EPCs to tumor site might be due
to expression of several factors in tumor cells, predom-
inately expression of SDF-1 or RANTES, which enhance
the migration of EPCs and CTLs to tumor site [17]. Ac-
cumulation of CTLs and EPCs at tumor site wasFigure 4 Histological analysis of brain tumors that received CTLs and
positive cells in tumors that received CTLs or EPCs (arrows), which indicate
magnification was used to show the overview of the brain section with tum
labeled CTLs and EPCs to the tumor area. We also enlarged 40× images toincreased significantly at 24 hours of post injection. This
is due to redistribution of CTLs and EPCs from the lung
and other organs to the tumor site.
Biodistribution studies of CTLs and EPCs are critical
requirement before applying them in clinical studies. In
this study we observed migration patterns to lung, liver,
and spleen, upon IV injection of CTLs and EPCs. We
observed cells migration to lung within hour of systemic
injection. Normally, systemically administered cells
quickly reach to the heart and travel through pulmonary
vasculatures. We observed that cell associated signal
from lung was higher at early time points upon systemic
injection of CTLs and EPCs. Compared to other organs,
lung have microvasculature, which has potential to trap
injected cells based on their morphology and adhesion
properties [23]. Cells like EPCs can be cleared from lung
quickly compared to other cell types such as mesenchy-
mal stem cells (MSCs), which showed higher accumula-
tion and longer retention before redistribution into
inflammation sites [23]. We observed reduction of activ-
ity from 38% to 3% in lung within 24 hours of post injec-
tion of EPCs, which was further reduced after 72 hours.
These results indicated that EPCs and CTLs were
redistributed faster rate from lung might be due to their
smaller size. In addition, we observed an increased activ-
ity around the tumor area after 24 hours post injection,
which further confirms redistribution of EPCs and CTLs
from lung to tumor area. We also observed redistribu-
tion of EPCs, which was much faster than CTLs. EPCs
showed a rapid clearance from the lung (38% to 12% inEPCs. DAB enhanced prussian blue staining show multiple iron
s migration and homing of CTLs and EPCs into tumor area. 4×
or region. 40× magnification was used to show the migration of iron
show the intact cells.
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hours (30%ID). This observation might be due to the
natural phenomenon of EPCs to migrate quickly to the
sites of lesions [26]. On other hand, T-cell upon
sensitization with DC begin macromolecular synthesis
and enlargement of cytoplasmic volume and the cells
size could reaches up to 10–30 μm in diameter [27].
This might be the reason for slow rate of clearance of
CTLs from lung.
In this study, we did not evaluate any therapeutic ef-
fect of administered cells (CTLs, EPCs) on the glioma.
The study was designed to evaluate degree of cell reten-
tion in different organs following IV administration,
biodistribution patterns, and dose design. The use of the
SPECT imaging method in combination with In-111-
oxine has been validated as an effective means of cell
tracking method to study the biodistribution of adminis-
tered cells. The data generated in this study can be used
to study the timing of injection as well as number of
cells accumulation at tumor site. This study also allows
calculating the timing for secondary therapeutic dose
and retention strategies. In addition, information gener-
ated in this study further helps to utilize these cells to
deliver therapeutic agents to glioma.
Conclusion
SPECT studies were able to show the differential bio-dis-
tribution of In-111-oxine, EPCs and CTLs in different
organs and intracranial glioma. Distribution of In-111-
oxine alone in different organs remained identical from
day 0 to day 3 except slight increased activity in spleen.
Both CLTs and EPCs redistributed from lung to other
organs within 24 hours.
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